KPW
AIMT

Kore Private Wealth’s Aimmune Therapeutics AIMT Stock Holding History

Kore Private Wealth’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,953
Closed -$32K – 1211
2020
Q2 		$32K Buy
1,953
+103
+6% +$1.75K 0.01% 559
2020
Q1 		$27K Sell
1,850
-750
-29% -$19.2K 0.01% 541
2019
Q4 		$87K Buy
+2,600
New +$72.7K 0.02% 395
2019
Q2 		– Sell
-2,450
Closed -$55K – 861
2019
Q1 		$55K Hold
2,450
– – 0.01% 370
2018
Q4 		$59K Buy
+2,450
New +$63.4K 0.02% 342

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kore Private Wealth's AIMT Position: Q3 2020 in Review

Kore Private Wealth sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 1,953 shares — an estimated $32K sold.

Kore Private Wealth first reported a position in AIMT in Q4 2018 and held it in 5 quarters. The position peaked at $87K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Kore Private Wealth reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 1,953 Aimmune Therapeutics shares in Q3 2020, an estimated $32K.
  • Kore Private Wealth first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 5 quarters.
  • Kore Private Wealth's Aimmune Therapeutics position peaked at $87K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.